Gastrointestinal Pathogens Panel (GPP)*


Gastroenteritis is the second most common illness after the common cold. Globally, diarrhea accounts for approximately 2 million deaths in children less than 5 years old, or 19% of total child deaths.1, Diarrheal pathogens include viruses, bacteria and parasites.

Clinical laboratories typically rely on the combination of conventional microbiological methods and molecular methods, and can cause delays in identification of gastrointestinal pathogens. For rapid identification of the pathogens that can cause outbreaks of diarrhea, a rapid multiplex front line screening assay is highly desirable and would be helpful in infection control. In the case of C. difficile infections, a rapid identification may not only reduce nosocomial transmission but favor the clinical outcome by initiating more timely and specific therapy.3

Applied BioCode is currently developing a Gastrointestinal Pathogen Panel for common gastrointestinal (GI) pathogens including viruses, bacteria and parasites that cause infectious diarrhea. The Applied BioCode GPP* is run in a low cost, high throughput 96 well microplate format. It will simultaneously detect and differentiate the presence of 18 diarrhea-causing pathogens in stool providing more GI pathogenic targets than other high throughput systems on the market. The Applied BioCode GPP* will be available on our new BioCode MDx 3000 System* which will combine the amplification, hybridization, and detection steps for this assay. The automation of these steps into a single system will decrease costs, hands on time, and minimize potential contamination risk.


Applied BioCode GPP*
    • Campylobacter
    Clostridium difficile toxins A and B
    E. coli O157
    • Enteropathogenic E. coli (EPEC)
    • Enterotoxigenic E. coli LT/ST (ETEC)
    • Salmonella
    • Shiga-like toxin producing E. coli stx1/stx2 (STEC)
    • Shigella/ Enteroinvasive E. coli (EIEC)
    • Vibro/ Vibro parahemolyticus
    Yersinia enterocolitica
    • Adenovirus 40/41
    • Norovirus GI/GII
    • Rotavirus A
    Entamoeba histolytica
    Giardia lamblia
Internal Control
    • MS2


* The product is currently Under Development.

For More Information:

For more information about the technology of any of these products or to discuss a potential study, please contact us via:


    1. Boschi-Pinto C, Velebit L, Shibuya K. Estimating child mortality due to diarrhoea in developing countries. Bull World Health Organ. 2008; 86(9):710–7.
    2. Clark B, McKendrick M. A review of viral gastroenteritis. Curr Opin Infect Dis. 2004; 17(5):461–9.
    3. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. (2010) Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 31(5):55–431.